Skip to main content

Table 3 Clinical outcomes of low dose HES vs moderate dose HES group

From: Impact of 6% balanced hydroxyethyl starch following cardiopulmonary bypass on renal function: a retrospective study

Variables Low dose HES
(n = 1239)
Moderate dose HES
(n = 418)
p-value
Acute kidney injury 78 (6.3) 45 (10.7) .02
 RIFLE (Risk) 56 (4.5) 34 (8.1)  
 RIFLE (Injury) 18 (1.4) 8 (1.9)  
 RIFLE (Failure) 4 (0.3) 3 (0.7)  
 KDIGO 101 (8.2) 57 (13.6) .02
New renal replacement therapy 40 (3.2) 18 (4.3) .30
ICU stay, days 2.9 ± 7.7 2.9 ± 2.8 .003
30-day mortality 21 (1.6) 7 (1.6) .97
Mortality after 30-day 37 (2.9) 22 (5.2) .03
  1. Results are presented as mean ± standard deviation or number (percentage). HES Hydroxyethyl starch; RIFLE Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease classification to define and stratify the severity of acute kidney injury; KDIGO Kidney disease improving global outcomes; ICU Intensive care unit